Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966941320> ?p ?o ?g. }
- W1966941320 endingPage "303" @default.
- W1966941320 startingPage "296" @default.
- W1966941320 abstract "Traditional medical treatments for ulcerative colitis (UC) are still compromised by its adverse effects and not potent enough to keep in remission for long-term periods. So, new therapies that are targeted at specific disease mechanisms have the potential to provide more effective and safe treatments for ulcerative colitis. Probiotics is recently introduced as a therapy for ulcerative colitis. In the present study, Lactobacillus acidophilus was selected as a probiotic therapy to investigate its effects in oxazolone-induced colitis model in rats that mimics the picture in human. The rats were grouped (8 rats each) as normal control group (Group I), Group II served as untreated oxazolone-induced colitis, Group III oxazolone-induced colitis treated with probiotic L. acidophilus (1×10(7) colony-forming units (CFU)/mL/day oral for 14 days), Group IV oxazolone-induced colitis treated with olsalazine (60 mg/kg/day oral for 14 days), Group V oxazolone-induced colitis treated with probiotic L. acidophilus and olsalazine in the same doses and duration. Disease activity index (DAI) was recorded, serum levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and intrleukin-6 (IL-6) was assessed as inflammatory markers and the histopathological picture of the colon of each rat was studied. Disease activity index (DAI) showed significant positive correlation with the elevated serum levels of CRP (r=0.741, p<0.05), TNF-α (r=0.802, p<0.05) and IL-6 (r=0.801, p<0.05). Treatment with either L. acidophilus (group III) or olsalazine (group IV) resulted in significant reduction in serum levels of CRP, TNF-α and IL-6, as well as disease activity index (DAI). Treatment with combination of L. acidophilus and olsalazine (group V) offered more significant reduction in serum levels of CRP, TNF-α, IL-6 and disease activity index (DAI) when compared to either group II (untreated group), group III (treated with L. acidophilus) or group IV (treated with olsalazine). So, it was concluded that L. acidophilus probiotic could be recommended as adjuvant therapy in combination with olsalazine to achieve more effective treatment for ulcerative colitis. For application in human, this needs to be verified in further clinical studies." @default.
- W1966941320 created "2016-06-24" @default.
- W1966941320 creator A5041431546 @default.
- W1966941320 creator A5065043350 @default.
- W1966941320 date "2008-12-01" @default.
- W1966941320 modified "2023-09-25" @default.
- W1966941320 title "An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “olsalazine”" @default.
- W1966941320 cites W12904408 @default.
- W1966941320 cites W1501964179 @default.
- W1966941320 cites W1583799593 @default.
- W1966941320 cites W1829239725 @default.
- W1966941320 cites W1941112737 @default.
- W1966941320 cites W1974424681 @default.
- W1966941320 cites W1976056371 @default.
- W1966941320 cites W1977968890 @default.
- W1966941320 cites W1981227935 @default.
- W1966941320 cites W1982326403 @default.
- W1966941320 cites W1989296532 @default.
- W1966941320 cites W1992421334 @default.
- W1966941320 cites W1994676778 @default.
- W1966941320 cites W1998930597 @default.
- W1966941320 cites W2014818191 @default.
- W1966941320 cites W2016459879 @default.
- W1966941320 cites W2040989977 @default.
- W1966941320 cites W2047957620 @default.
- W1966941320 cites W2048304047 @default.
- W1966941320 cites W2055703654 @default.
- W1966941320 cites W2067447558 @default.
- W1966941320 cites W2070329738 @default.
- W1966941320 cites W2072593316 @default.
- W1966941320 cites W2078745520 @default.
- W1966941320 cites W2083151325 @default.
- W1966941320 cites W2084990572 @default.
- W1966941320 cites W2086894949 @default.
- W1966941320 cites W2088313490 @default.
- W1966941320 cites W2091150708 @default.
- W1966941320 cites W2093991815 @default.
- W1966941320 cites W2099376515 @default.
- W1966941320 cites W2101467275 @default.
- W1966941320 cites W2108241562 @default.
- W1966941320 cites W2113855055 @default.
- W1966941320 cites W2115625081 @default.
- W1966941320 cites W2120563211 @default.
- W1966941320 cites W2122039020 @default.
- W1966941320 cites W2131691027 @default.
- W1966941320 cites W2133661387 @default.
- W1966941320 cites W2136422620 @default.
- W1966941320 cites W2141439571 @default.
- W1966941320 cites W2147150861 @default.
- W1966941320 cites W2150605496 @default.
- W1966941320 cites W2156807154 @default.
- W1966941320 cites W2157709517 @default.
- W1966941320 cites W2164381959 @default.
- W1966941320 cites W2164525350 @default.
- W1966941320 cites W2165457181 @default.
- W1966941320 cites W2172219164 @default.
- W1966941320 cites W2312575430 @default.
- W1966941320 cites W2412588445 @default.
- W1966941320 cites W2557759644 @default.
- W1966941320 cites W4292994528 @default.
- W1966941320 doi "https://doi.org/10.1016/j.crohns.2008.04.002" @default.
- W1966941320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21172227" @default.
- W1966941320 hasPublicationYear "2008" @default.
- W1966941320 type Work @default.
- W1966941320 sameAs 1966941320 @default.
- W1966941320 citedByCount "25" @default.
- W1966941320 countsByYear W19669413202012 @default.
- W1966941320 countsByYear W19669413202015 @default.
- W1966941320 countsByYear W19669413202016 @default.
- W1966941320 countsByYear W19669413202017 @default.
- W1966941320 countsByYear W19669413202018 @default.
- W1966941320 countsByYear W19669413202019 @default.
- W1966941320 countsByYear W19669413202020 @default.
- W1966941320 countsByYear W19669413202021 @default.
- W1966941320 countsByYear W19669413202022 @default.
- W1966941320 crossrefType "journal-article" @default.
- W1966941320 hasAuthorship W1966941320A5041431546 @default.
- W1966941320 hasAuthorship W1966941320A5065043350 @default.
- W1966941320 hasBestOaLocation W19669413201 @default.
- W1966941320 hasConcept C126322002 @default.
- W1966941320 hasConcept C203014093 @default.
- W1966941320 hasConcept C2775862500 @default.
- W1966941320 hasConcept C2777221637 @default.
- W1966941320 hasConcept C2778260677 @default.
- W1966941320 hasConcept C2779134260 @default.
- W1966941320 hasConcept C2779790080 @default.
- W1966941320 hasConcept C2780255968 @default.
- W1966941320 hasConcept C2780479503 @default.
- W1966941320 hasConcept C523546767 @default.
- W1966941320 hasConcept C54355233 @default.
- W1966941320 hasConcept C71924100 @default.
- W1966941320 hasConcept C86803240 @default.
- W1966941320 hasConcept C90924648 @default.
- W1966941320 hasConceptScore W1966941320C126322002 @default.
- W1966941320 hasConceptScore W1966941320C203014093 @default.
- W1966941320 hasConceptScore W1966941320C2775862500 @default.
- W1966941320 hasConceptScore W1966941320C2777221637 @default.
- W1966941320 hasConceptScore W1966941320C2778260677 @default.